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Abstract
Objective To assess patient preferences for two osteoporosis
medications.
Design Women aged 50+ were surveyed via the Internet to assess
preferences for two osteoporosis medication proﬁles. Drug A and
Drug B, consistent with ibandronate and alendronate, respectively,
diﬀered by: time on market (recently vs. 10 years), dosing frequency
(monthly vs. weekly), eﬀectiveness (not proven vs. proven to reduce
non-spine or hip fracture after 3 years) and dosing procedure (60 vs.
30 min wait before eating/drinking). Each proﬁle had the same out-
of-pocket costs, side-eﬀects, potential for drug interaction and spine
fracture eﬃcacy. Patients force ranked and rated the importance of
each attribute. Subgroup comparisons included diagnosed vs. at-risk
respondents and treated vs. untreated respondents.
Results Among the 999 respondents, Drug B was preferred by 96%.
Eﬀectiveness was ranked as the most important determinant of
preference (79% ranked it #1) compared with time on market
(14%), dosing procedure (4%) and dosing frequency (3%). Eﬀect-
iveness had the highest mean importance rating on a scale of 1
(extremely unimportant) to 7 (extremely important): mean (SD) ¼
6.1 (1.8), followed by time on market: 4.7 (1.7), dosing procedure:
4.6 (1.4) and dosing frequency: 4.5 (1.4). No signiﬁcant diﬀerences in
proﬁle choice were found across study subgroups.
Conclusions The drug proﬁle showing reductions in non-vertebral
and hip fracture risk was chosen by almost all respondents. Drug
eﬀectivenesswas themostimportantdeterminantofpreference, while
dosing frequency was the least important determinant. Incorporation
of patient preferences in the medication decision-making process
could enhance patient compliance and clinical outcomes.
Introduction
There are several FDA-approved medications on
the market today for the prevention and treat-
ment of post-menopausal osteoporosis. As a
result, women with osteoporosis, and their doc-
tors, have to decide on a given medication choice
while weighing a number of crucial medication
attributes, such as risks (i.e. safety, tolerability,
adverse events and untoward quality-of-life
sequelae), beneﬁts (i.e. clinical eﬀectiveness),
convenience and costs. The most widely
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the prevention and treatment of osteoporosis
are the oral bisphosphonates, which include
alendronate and risedronate (daily or weekly
dosing)andibandronate(monthlydosing).Other
available osteoporosis therapies include oestro-
gen/hormone therapy (available in both oral and
patch), calcitonin (nasal spray), teriparatide
(injectable parathyroid hormone), raloxifene
(daily oral selective oestrogen receptor modu-
lator) and intravenous ibandronate.
Despite the demonstrated clinical beneﬁts
associated with bisphosphonate therapy, adher-
ence is poor.
1–10 Although it is diﬃcult to aver-
age estimates across studies whose designs and
operational deﬁnitions diﬀer greatly, approxi-
mately one half of women discontinue pre-
scription therapy for osteoporosis in the ﬁrst
12 months.
1–10 The reasons underlying medica-
tion non-adherence are multifactorial, involving
both patients and doctors. Patient-level deter-
minants of poor adherence in osteoporosis
include side-eﬀects (particularly upper gastroin-
testinal side-eﬀects), patients lack of belief in the
beneﬁts of treatment, patients subjective
assessment of the seriousness of osteoporosis,
the asymptomatic nature of osteoporosis (until a
fracture occurs), the complexity of the bisphos-
phonates treatment regimen, the need for long-
term treatment and ﬁnancial costs associated
with treatment.
11–13 Doctors, on the other hand,
contribute to patients poor adherence by failing
to adequately explain the beneﬁts and side-
eﬀects of medications and failing to consider
patients lifestyle and out-of-pocket costs of
medication.
14 Adding complexity to the prob-
lem, the ability of doctors to ascertain and
improve non-adherence is poor.
14 The clinical
consequences of poor adherence are noteworthy:
poor adherence with osteoporosis medications
results in smaller increases in bone mass den-
sity
15 and a greater risk of fracture.
2,4,15–17
It is likely that both patient adherence and
patient satisfaction can be improved when doc-
tors incorporate patient preferences into treat-
ment decision-making. Patient preferences
represent a real-life, omnibus valuation of var-
iousmedicationand/ortreatmentattributes,such
as eﬃcacy, tolerability, convenience, ﬁnancial
costs and ease of use, among others.
18–21 In real
life, patients are the ones who experience the
inconvenience of treatment, their side-eﬀects,
their economic impact and their quality of life
sequelae.
18 If patients do not accept their treat-
mentanddonotpersistwiththerapy,thenclinical
eﬀectiveness is degraded and economic resources
are wasted. Accounting for patient preferences
is especially important when patients have
chronic conditions and need to be informed
partners in decision-making at almost every
action point.
22
A variety of related terms (collaborative care,
patient-centred care, shared decision-making)
have been used to describe the processes of joint
decision-making between the patient and health-
care provider. If patients are to participate in
medication decisions, they must understand the
potential beneﬁts and risks associated with
available medications as well as the potential
impact of these medications on their everyday
quality of life. If health-care providers are to
embrace patient-centred care, they must under-
stand patient preferences for their care. For
doctors to make evidence-based decisions about
medication choices with their patients, they must
elicit from patients their preferences for the
range of relevant medication attributes.
18
Given the recent proliferation of diﬀerent
prescription medications for osteoporosis, there
is a pressing need for more information about
patient preferences for diﬀerent attributes of
osteoporosis medications to facilitate the colla-
borative care process in osteoporosis care. The
purpose of this research was to evaluate patient
preferences for two osteoporosis medication
proﬁles among post-menopausal women with
osteoporosis or at risk for osteoporosis, whether
or not they are currently receiving treatment.
The results of this study may facilitate shared
decision-making in osteoporosis care by provi-
ding clinicians insight into what medication
attributes drive patients to prefer one osteo-
porosis medication over another. Such know-
ledge of patient preferences is especially relevant
today because both primary and specialty care
providers now have the option of oﬀering
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2122 weekly and 1 monthly osteoporosis prescrip-
tion medications to their patients for the pre-
vention or treatment of osteoporosis.
Research design and methods
Over the past several years, weekly bisphos-
phonates (alendronate and risedronate) have
become the mainstay of prescription osteopor-
osis therapy. In 2005, however, a once monthly
bisphosphonate (ibandronate) entered the
osteoporosis market. Recent literature has sug-
gested that, in the absence of patient knowledge
about medication attributes other than dosing
frequency, osteoporosis patients tend to prefer a
monthly dosing schedule.
23 Further, some have
hypothesized that monthly dosing should lead to
better medication adherence,
24 although this
clearly remains an outstanding empirical
research question.
It was on this foundation that we designed a
study to elicit patient preference for two drug
proﬁles similar to weekly alendronate and
monthly ibandronate among post-menopausal
women. The proﬁles were composed of four key
osteoporosis medication attributes: (i) time on
market; (ii) dosing frequency; (iii) drug eﬀective-
ness and (iv) dosing procedure. We used infor-
mationfromthepeer-reviewed literature
25–27and
theindividualproductinsertstobuildtheproﬁles.
Our speciﬁc aims were to determine: (i) which
osteoporosis medication proﬁle patients pre-
ferredand(ii)theimportance patientsassignedto
four osteoporosis medication attributes when
choosing between the two medication proﬁles.
Sampling scheme and study cohort
The sample consisted of a cohort of selected
respondents to either the 2003 or the 2004
National Health and Wellness Survey (NHWS,
http://www.nhwsurvey.com). The NHWS is a
cross-sectional survey of adult consumers (age
18+) attitudes, behaviours and treatment
choices as they relate to health care. The NHWS
is an Internet-based survey administered annu-
ally in the US by Consumer Health Sciences.
Respondents for the survey were identiﬁed from
a national Internet panel maintained by Harris
Interactive (http://www.harrisinteractive.com).
Additional methods of the PREFER-US study,
speciﬁcally the sampling scheme and rationale,
have been described in detail elsewhere.
28 This
study was approved by the Essex IRB.
The eligible study cohort consisted of women
age 50 or older with osteoporosis or at risk for
osteoporosis. Respondents who reported in the
NHWS or the PREFER survey as having been
diagnosed by a doctor as having osteoporosis
were classiﬁed as diagnosed. Those not classi-
ﬁed as diagnosed, but stated in the NHWS they
were at risk or had a family history, were
classiﬁed as at risk. Speciﬁcally, at-risk res-
pondents stated yes in the NHWS to Do you
think you are at risk for osteoporosis? or stated
in the NHWS that they had a family history of
osteoporosis.
Patients with a history of osteoporosis or at
risk for osteoporosis were chosen for study
because we believed that prescription osteopor-
osis medication choices would be relevant to
them as it is likely that they would either be
prior/current users of osteoporosis medication
(i.e. diagnosed patients) or future users of
osteoporosis medication (i.e. at-risk patients).
Survey design and administration
The PREFER survey was developed using input
from four focus groups of women 50 years or
older and from existing literature on patient
preferences.
28 Brieﬂy, the survey consisted of the
following: e-mail invitation and consent to par-
ticipate in the study, demographic information,
current prescription osteoporosis medication
usage, items assessing self-reported convenience
of taking osteoporosis medications and several
item formats to assess preferences for osteo-
porosis medication attributes, including the
medication proﬁle that is the focus of this ana-
lysis. The entire survey was accessed and
administered on-line. Additional details of the
survey design can be found elsewhere.
28
Osteoporosis medication preferences were
assessed by comparing the proﬁles of Drug A
and Drug B (see Table 1). No brand names were
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213mentioned in the survey. The proﬁle stated that
the two medications had the same out-of-pocket
costs, side-eﬀects, potential for drug interaction
and ability to reduce the risk of spine fracture.
The proﬁle also stated that the two drugs diﬀered
by the following attributes: time on market
(recently vs. 10 years); dosing frequency
(monthly vs. weekly); drug eﬀectiveness (not
proven vs. proven to reduce non-spine or hip
fracture after 3 years); and dosing procedure (60
vs. 30 min wait after taking). These attributes are
consistent with two osteoporosis medications
currently on the market for the prevention and
treatment of post-menopausal osteoporosis
(ibandronate and alendronate, respectively).
25–27
Change in bone mineral density (BMD) was
notusedtoillustratedrugeﬀectivenessforseveral
reasons. First, from our focus group research, we
learned that fractures and their consequences
were better understood by women than clinical
markers such as BMD, which only provides evi-
denceoftheantiresorptiveactivityoftreatment.
29
Secondly, the clinical literature in osteoporosis is
dividedontheissueofhowmuchchangeinBMD
accounts for observed fracture risk reduction
during antiresorptive therapy.
30,31 Finally, our
use of fracture risk reduction to deﬁne the medi-
cation eﬀectiveness attribute, rather than change
in BMD, is consistent with previous research on
osteoporosis treatment preferences.
32
Respondents were asked to: (i) select between
the two osteoporosis medication proﬁles; (ii)
force-rank order, from 1 to 4, the four attributes
according to their reason for selecting their
preferred drug and (iii) separately rate the
importance of each of the four attributes on a
Likert-type scale from 1 (extremely unimpor-
tant) to 7 (extremely important) in determining
their selection of their preferred drug. The pri-
mary research questions were: (i) when presen-
ted with two osteoporosis medication proﬁles,
consistent with two available prescription treat-
ment options, what is the preferred choice
among women survey respondents with or at
risk for osteoporosis; (ii) which particular
medication attributes drove respondents drug
proﬁle choice and (iii) do drug proﬁle prefer-
ences diﬀer across patient subgroups?
Table 1 Medication proﬁle comparison question
Below are two hypothetical proﬁles of oral osteoporosis drugs. Assume that your doctor offers you a choice of either Drug A or
Drug B. Both have the same out-of-pocket costs, similar side-effects, and potential for drug interactions
Please take a moment to review the information below and answer the questions
Drug A Drug B
How long the drug has been on the
market
The drug has recently been introduced
to the market
The drug has been on the market for
10 years
How often you take the drug Once a month Once a week
How effective the drug is in reducing
the risk of fractures due to
osteoporosis
Spine fracture:
Proven to reduce the risk of having a
spine fracture within 3 years
Spine fracture:
Proven to reduce the risk of having a
spine fracture within 3 years
Non-spine fracture:
Not proven to reduce the risk of having
a non-spine fracture
Non-spine fracture:
Proven to reduce the risk of having a
non-spine fracture within 3 years
Hip fracture:
Not proven to reduce the risk of having
a hip fracture
Hip fracture:
Proven to reduce the risk of having a
hip fracture within 3 years
Procedure for taking the drug Take it ﬁrst thing in the morning and wait
at least 60 min before lying down,
drinking, eating or taking other
prescription drugs
Take it ﬁrst thing in the morning and
wait at least 30 min before lying down,
drinking, eating or taking other
prescription drugs
Based on the information presented in the table above, which drug would you prefer as a treatment for your bone health?
(Check only one box)
u Drug A u Drug B
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214Analytical approach
The primary outcome measure was the per-
centage of respondents that choose one or the
other of the two medication proﬁles. The sec-
ondary outcomes were the forced ranking
(heretofore called rankings) and the importance
ratings of the four medication attributes. Ana-
lyses were conducted for the total sample and by
subgroups (i.e. diagnosed vs. at risk for osteo-
porosis and treated vs. untreated for osteopor-
osis). Treatment was deﬁned as current use of
any of the following osteoporosis medications:
risedronate, raloxifene, teriparatide, alendro-
nate, calcitonin or ibandronate. We ﬁrst used a
chi-square with three degrees of freedom to test
for diﬀerence in the rankings of the four medi-
cation attributes for the subgroup comparisons
(diagnosed vs. at-risk and treated vs. untreated).
When the overall chi-square was signiﬁcant, we
then used chi-square to investigate subgroup
diﬀerences for each medication attribute by
comparing the percentage in each subgroup that
ranked the attribute as #1 vs. #2–4 combined.
The eﬀects of age, race, education, income and
prior fracture history on proﬁle preference were
also analysed using the chi-squared test.
Diﬀerencesinmeanimportanceratingswithina
subgroup (e.g. diagnosed respondents) between
the drug eﬀectiveness attribute and each of the
other three attributes were assessed separately for
each attribute comparison by subtracting the
rating score of drug eﬀectiveness from the rating
score for the other attribute. A paired t-test was
then performed for this diﬀerence. Then, to
determine diﬀerences in mean importance ratings
between subgroups (e.g. diagnosed vs. at-risk) for
eachattribute,weusedindependentsamplet-tests.
Results
Sample characteristics
Wecollected 999responsesafterthree fulldaysof
ﬁelding.Atthecloseofbusinessofthethirddayof
ﬁelding, we exceeded our target sample size and
stopped accepting questionnaires. As shown in
Table 2, the mean age of respondents was 65, the
vast majority were white (92%), and slightly over
one-half were currently married. Slightly more
the one-half (58%) were diagnosed with osteo-
porosis and somewhat less than one-half (42%)
were currently being treated for osteoporosis.
There were 578 respondents diagnosed with
osteoporosis and 421 respondents classiﬁed as at
risk. Compared to those classiﬁed as at-risk,
diagnosed respondents were slightly older, more
likelytobewidowedandretired,andless likelyto
have achieved a college education.
28 Of the total
sample, 421 respondents reported taking one or
more prescription osteoporosis medications, and
578 reported taking no medication for osteopor-
osis. The treated sample was signiﬁcantly older
and more likely to be widowed and retired.
28
Preference of osteoporosis medication proﬁle
The proﬁle labelled Drug B (designed to
approximate alendronate) was preferred by 96%
of respondents. In the subgroup analyses, Drug
B was chosen by 95% of the diagnosed
respondents, 97% of the at-risk respondents,
96% of the treated respondents and 96% of the
untreated respondents. The proﬁle preference
was invariant across demographics and fracture
history (data not shown).
Rankings and importance rating of prescription
osteoporosis medication attributes
As shown in Table 3, 79% of the sample ranked
drug eﬀectiveness (e.g. ability to reduce the risk
of fractures) as the #1 reason for preferring
Table 2 Demographic proﬁle of responders
Responders
(n ¼ 999)
Age (years), mean (SD) 65.1 (8.2)
White 918 (93%)
Married 548 (55%)
Employed 321 (32%)
College education 393 (39%)
Income <$35 000 346 (44%)
Adults household size (median, range) 2 (1–20)
Diagnosed with osteoporosis 578 (58%)
Treated for osteoporosis 421 (42%)
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215Drug B over Drug A, followed by time on
market (14%), and dosing procedure (4%).
Dosing frequency was the lowest ranked attrib-
ute, with only 3% of the sample ranking it as
their #1 reason for choosing between the two
drug proﬁles.
Figure 1a shows the comparison of the #1
ranked attributes for diagnosed vs. at-risk sub-
groups which were signiﬁcantly diﬀerent (P ¼
0.04). Comparing those diagnosed with osteo-
porosis vs. those at-risk, 81% and 77%,
respectively, force ranked drug eﬀectiveness as
the #1 reason for choosing between the two
proﬁles. Eleven percentage of the diagnosed
group ranked time on market #1 vs. 17% of the
at-risk group. The treated and untreated sub-
groups diﬀered signiﬁcantly (P ¼ 0.002) in the
#1 rankings of attributes (Fig. 1b). Among the
treated, 83% ranked drug eﬀectiveness as their
#1 proﬁle driver, while 76% of the untreated
group ranked it as such. Nine percentage of the
treated group ranked time on market #1 vs. 17%
of the untreated.
As shown in Table 4 for the total sample,
drug eﬀectiveness had the highest percentage
of extremely important responses (68%) in
Table 3 Forced ranking of osteoporosis medication proﬁle
attributes: total sample (n ¼ 999)
Attribute*
Forced rankings
1st 2nd 3rd 4th
Drug effectiveness (%) 79 16 4 2
Time on market (%) 14 33 16 38
Dosing procedure (%) 42 7 3 23 6
Dosing frequency (%) 32 4 4 82 4
*Attributes ordered from highest rank based on highest (#1) ranking
to lowest (#4) rank.
3
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Figure 1 (a) #1 ranked attribute for osteoporosis medication
proﬁle by osteoporosis status. (b) #1 ranked attribute for
osteoporosis medication proﬁle by osteoporosis treatment
status.
Table 4 Percentage distribution of importance ratings for osteoporosis medication proﬁle attributes: total sample (n ¼ 999)*
Importance ratings

Extremely
important
(%)
Very
important
(%)
Somewhat
important
(%)
Neither
important
nor
unimportant
(%)
Somewhat
unimportant
(%)
Very
unimportant
(%)
Extremely
unimportant
(%)
Mean
(SD) Median
Drug effectiveness
 68 17 3 1 0 2 9 6.1 (1.8) 7
Time on market 15 20 25 15 11 8 5 4.7 (1.7) 5
Dosing procedure 82 13 1 2 2 1 0 7 2 4 .6 (1.4) 5
Dosing frequency 71 63 5 2 0 1 1 8 3 4 .5 (1.4) 5
*Percentages may not add to 100% due to rounding error. Attributes ordered from highest rating (based on % rating extremely important) to
lowest rating.
Drug effectiveness signiﬁcantly different from time on market, dosing procedure and dosing frequency (P < 0.0001) for overall comparison.
Scale ranges from Extremely Important (7) to Extremely Unimportant (1).
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216determining the proﬁle choice, followed by time
on market (15%). Dosing procedure and dosing
frequency had the lowest percentages of extre-
mely important responses (8% and 7%,
respectively) in determining the proﬁle choice.
For the total sample (Table 5), drug eﬀective-
ness had the highest mean importance rating
(mean ¼ 6.1, SD: 1.8), which was signiﬁcantly
higher than the other three attributes
(P < 0.0001 for all paired comparisons).
Signiﬁcantly higher mean importance ratings for
drug eﬀectiveness relative to the other three
attributes were invariant across subgroups
(P < 0.0001).
The distributions of importance ratings for
the dosing procedure attribute diﬀered between
the diagnosed and at-risk subgroups (data not
shown). One-third (32%) of the diagnosed sub-
group rated dosing procedure as very or
extremely important compared with 23% of
those at risk (P ¼ 0.005). The distributions of
importance ratings for the time-on-market and
dosing-frequency attributes diﬀered between the
treated vs. untreated subgroups (data not
shown). Less then one-third (29%) of treated
respondents rated time on market as very or
extremely important compared with 39% of
those untreated (P ¼ 0.0009). One-ﬁfth (21%)
of untreated respondents rated dosing frequency
as very or extremely important compared with
27% of those treated (P ¼ 0.0009).
Discussion
The past 16 years has been characterized as the
era of outcomes assessment, in which the per-
spective of the patient – their quality of life,
satisfaction with care and treatment preferences
– has come to be regarded as a key component in
understanding and monitoring the quality and
eﬀectiveness of medical care. Patient preference
research, in particular, has burgeoned in the last
few years for several reasons. For one, the
number and types of pharmaceutical products
have mushroomed in recent years, thereby
oﬀering payers, doctors and patients choices
among drugs that may or may not diﬀer sub-
stantially with respect to eﬃcacy (depending on
how eﬃcacy is measured) but certainly diﬀer on
other attributes that matter to patients, such as
convenience, costs and lifestyle disruption. Fur-
ther, the Internet has made it easier for patients
to readily access medically related information,
including information on treatment options
from online health information services, online
support groups and direct-to-consumer pre-
scription drug websites. Finally, direct-to-con-
sumer advertising on television and in print has
made patients more informed about treatment
options for many conditions.
Recently, John Wennberg, one of the fathers
of the outcomes movement, coined the term
preference-sensitive care,
33 which is clinical
services where at least two valid alternative
treatment strategies are available. In preference-
sensitive decisions, the optimal choice depends
on patients’ values or preferences for the
beneﬁts and harms of each option.
34 While the
patient outcomes movement has enlightened us
about how satisﬁed patients are with their health
care and their behavioural and emotional func-
tioning, we still have much to learn about what
aspects of treatment are important to patients
and preferred by them. Across a wide variety of
diseases, it has been asserted that fulﬁlment of
patient preferences, in terms of medication and
Table 5 Mean (SD) importance ratings

for osteoporosis medication proﬁle
attributes: by osteoporosis status and
treatment status
Attribute Diagnosed At risk Treated Untreated
Drug effectiveness* 6.1 (1.9) 6.1 (1.8) 6.1 (1.9) 6.1 (1.8)
Time on market
 4.5 (1.7) 4.9 (1.6) 4.5 (1.6) 4.8 (1.7)
Dosing procedure 4.7 (1.5) 4.6 (1.3) 4.7 (1.5) 4.6 (1.4)
Dosing frequency 4.6 (1.5) 4.5 (1.4) 4.6 (1.5) 4.5 (1.4)
*Drug effectiveness signiﬁcantly different from time on market, dosing procedure and dosing
frequency (P < 0.0001) within each subgroup (i.e. diagnosed, at risk, treated and untreated).
Time on market signiﬁcantly different between diagnosed and at-risk and between treated and
untreated groups (P < 0.05).
Scale ranges from Extremely Important (7) to Extremely Unimportant (1).
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217treatment attributes, could go far towards
improving short-term adherence and long-term
persistence with drug therapy.
23,35,36 This is an
issue of great consequence as medication non-
compliance is widespread,
37 costing patients and
society billions in direct and indirect health-care
costs,
37 diminishing the impact of therapy on
clinical and quality of life outcomes, and preci-
pitating further morbidity and, sometimes,
death.
Our preference study follows on the heels of
dozens of others published in the literature.
Assessment of patients treatment preferences
have assumed many methodological forms,
including standard survey-based ratings and
rankings of preferences (like our study) and
hypothetical treatment scenarios.
38,39 Conjoint
analysis and willingness-to-pay methods have
also been used to study treatment prefer-
ences
40,41 as well as preferences for diﬀerent
aspects of the processes of health-care deliv-
ery.
42,43 Preference studies have been conducted
in myriad therapeutic areas including, but not
limited to, acne,
44 allergic rhinitis (e.g. compar-
ing diﬀerent nasal sprays),
45 asthma (e.g. com-
paring diﬀerent inhalation therapies),
46 diabetes
(e.g. comparing diﬀerent modes of insulin
delivery),
47 erectile dysfunction,
48 GERD,
49
glaucoma,
50 HIV,
51 insomnia,
52 irritable bowel
syndrome,
53 migraine
20 and osteoporosis (e.g.
comparing drugs of the same class diﬀering in
dosing frequency
23,54–56).
In this study, 96% of sampled women with or
at risk for osteoporosis chose the medication
proﬁle consistent with alendronate which, when
compared with ibandronate, has a longer history
on the market, data supporting overall eﬀects on
non-vertebral and hip fracture risk reduc-
tion,
25,27 and a dosing procedure requiring less
time, but with more frequent dosing. This ﬁnd-
ing was observed across subgroups deﬁned by
osteoporosis risk status and osteoporosis treat-
ment status as well as by secondary demographic
subgroups (i.e. age, race, education, income,
prior fracture). Like preference studies in other
diseases,
20,36,57–61 we found drug eﬀectiveness to
be the #1 determinant of preferring the alendr-
onate proﬁle over the ibandronate proﬁle, with
79% of the sample force ranking drug eﬀect-
iveness as their #1 preference driver. Like pref-
erence studies in other diseases,
62,63 we found
that dosing frequency rated low in the drivers of
patients treatment proﬁle preference, with only
3% of the sample force ranking dosing fre-
quency as their #1 preference driver. Our ﬁnding
that almost all respondents preferred the drug
proﬁle with more evidence of fracture risk
reduction, albeit with more frequent dosing,
contrasts with studies showing that patients
prefer less frequent dosing.
23,54–56 In one such
crossover study,
23 patients were not informed
about the key attributes of the medications they
were taking and only reported preferences based
on the frequency of dosing or tolerability.
Our ﬁndings using the methods of forced
rankings were corroborated using importance
ratings. Drug eﬀectiveness had the highest per-
centage of extremely important responses (68%)
compared with 15% for time on market, 8% for
dosing procedure and 7% for dosing frequency.
Combining the two most positive importance
ratings (extremely and very), 85% of the sample
rated drug eﬀectiveness as extremely/very
important compared with 35% for time on
market, 29% for dosing procedure and 23% for
dosing frequency. The mean importance rating
was the highest for drug eﬀectiveness (6.1), and
it was signiﬁcantly higher than those for time on
market (4.7), dosing procedure (4.6) and dosing
frequency (4.5). The mean importance rating for
time on market was also signiﬁcantly higher
than that for dosing frequency.
We agree with the conceptualization of
patient preferences as a value judgement from
the patient point of view.
64 As such, patient
preference is a composite, patient-centred end
point that incorporates numerous treatment and
medication attributes,
18–21 albeit not all of which
are weighted equally by patients. Our use of two
well-accepted methods – forced rankings and
importance ratings – provided complimentary
evidence of such unequal weighing.
The general limitations of our study design
have been published elsewhere.
28 In brief, our
sample of responders had somewhat higher
socioeconomic status than the non-responders
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The literature provides no guidance as to whe-
ther preferences for osteoporosis medications
might vary as a function of socioeconomic status
and whether diﬀerent rankings and ratings
would have been obtained with a sample more
diverse in socioeconomic and ethnic character-
istics. Given the overwhelming choice respond-
ents made for Drug B, it is unlikely that these
diﬀerences would have any appreciable impact
on the study results. In addition, osteoporosis
diagnosis and at-risk status were based on self-
report rather than bone mineral density testing
used in clinical trials. It may be that a small
amount of misclassiﬁcation occurred using self-
reports. However, we do not think that this
would have appreciably aﬀected results given the
very close similarity of results between those
diagnosed vs. at risk and those treated vs.
untreated.
Another potential limitation of the study is
the presentation of the drug proﬁles. The
attributes for each drug proﬁle were presented
in one ﬁxed format (Table 1). We were careful
to present the key medication attributes in a
straightforward, easy to understand manner
based on existing literature regarding the
characteristics of each medication. In the
interest of brevity, we excluded information on
bone mineral density in the drug proﬁles. From
our focus group research prior to survey
development, patients were clearly more con-
cerned with fracture risk reduction than with
changes in bone mineral density. We do not
believe that the addition of information on
bone mineral density would change the con-
clusions of this study.
There are several clinical implications of our
study. As echoed by clinician scholars across
therapeutic areas,
18–21 we believe that patient
preferences provide a more real-life perspective
on medications and their attributes than is
reﬂected by clinical trial data, or product inserts.
As such, individual-level preference data could
provide clinicians with real time/real life infor-
mation on what matters to a patient and how
much. For example, many of our focus group
participants did not ﬁnd the procedure associ-
ated with taking weekly bisphosphonates intru-
sive to their lifestyle because they built new
habits around the requirements for taking it in
the morning without food and remaining
upright (e.g. taking the bisphosphonates and
going for a morning walk or taking a shower).
This observation underscores the fact that pref-
erences are subjective (i.e. some patients ﬁnd the
bisphosphonate procedure quite arduous while
others deem it undemanding) and can only be
ascertained by direct elicitation. Further, pref-
erences vary across patients, so it cannot be
assumed that what is considered inconvenient
for Mrs Jones will be interpreted as inconveni-
ent for Mrs Smith. As importantly, there is a
variance between patients and doctors percep-
tions of adherence barriers, with doctors over-
estimating the impact of doing frequency and
pill burden on compliance and underestimating
the inﬂuence of other medication attributes
valued by patients.
62
The basis of clinical medicine is treating
patients on an individual basis, but doctors often
prescribe therapy based on traditional eﬃcacy
end points derived from group-level clinical tri-
als. Tolerability and safety proﬁles are provided
to patients and doctors, yet patient-derived
information on convenience, ease of use, and
subjectiveeﬀectivenessratingsarerarelyincluded
in clinical trials and product inserts, even though
these medication attributes inﬂuence patient
perceptions of treatment acceptability and, ulti-
mately, compliance and therapeutic success. As
Dowson argues, the most important question is
not which prescription is best relative to another,
but whether the chosen prescription provides
the outcome desired by the patient and the
health-care provider.
65 A patient-centred and
preference-sensitive approach to medication
decision-making would allow for tailoring
various attributes of drug therapy to individual
patientneeds,particularlyfordisordersforwhich
there is more than one drug of the same or similar
class.Attentionto patientpreference fordiﬀerent
drug attributes may be particularly important in
asymptomatic conditions, like osteoporosis,
wherelong-termtherapy isrequiredforstabilized
or improved bone health and where patients may
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risk) and perceive the drawbacks of therapy to
exceed potential beneﬁts.
13,32
The therapeutic success of any medication is
dependent on the ﬁdelity with which patients
adhere to dosing procedure and instructions,
and such ﬁdelity is itself dependent on patient
attitudes and beliefs about their disease and
medication-taking in general as well as the
aggregate acceptability of a regimen to them.
45
Doctors may not be able to eﬀectively or quickly
change patient health and illness beliefs, but they
may have the ﬂexibility to prescribe medications
that meet patients needs for pill size, dosing
procedure, or dosing frequency or to prescribe
medications that minimize unpleasant side-
eﬀects or life-style disruption. To reach these
ends, though, doctors need to know what is
important to patients, and the only way to
achieve that end point to ask them. Hibbard
66
recently argued that patient preferences should
be considered as a vital sign to be regularly
monitored and attended to by doctors in clinical
practice. Hibbard’s recommendation is syn-
chronous with Don Berwick’s provocative
patient-centred axiom – nothing about me
without me.
67 Recent research has demonstra-
ted that not all patients wish to be the ﬁnal
arbiter of the medication decision; however, they
do want to be engaged in the decision-making
process by communicating beliefs, preferences
and desired outcomes to their clinicians.
68
Another recent study reported that about one
half of patients wanted to leave ﬁnal medical
decisions to the clinician, but that 96% wanted
to be oﬀered choices and to be asked their
opinion.
69
Numerous therapeutic options are currently
available for the prevention and treatment of
post-menopausal osteoporosis. Oral bisphos-
phonates are now available in daily, weekly
and monthly dosing regimens. However, it
would be both naive and premature to pre-
sume that monthly dosing will be a panacea
for the long-standing problems of lack of
adherence and persistence with therapy in
osteoporosis. First, movement from daily to
weekly dosing for osteoporosis has improved
persistence rates,
3,6,7,9,70 although they still
remain quite suboptimal even with weekly
dosing. Secondly, when women are asked why
they discontinue osteoporosis therapy, more
often than not, they oﬀer reasons other than
mere dosing frequency, in particular upper
gastrointestinal side-eﬀects,
11–13,71–73 safety
concerns,
13,71 medication costs
11–13 and lack of
motivation.
13 Thirdly, although research has
suggested that patients with osteoporosis have
preferences for less frequent dosing,
23,54–56 this
research has been conducted largely within the
context of open-label trials and without pro-
viding participants with information on how
comparator medications do or do not diﬀer on
other medications attributes valued by
patients, such as antifracture eﬃcacy, side-
eﬀects and costs, among others. Finally, com-
prehensive reviews of the literature on the
relationship between dosing frequency and a
variety of health outcomes have been limited
to studies of daily dosing, twice daily dosing
and multiple daily dosing.
74,75 Thus, it
remains unknown from other diseases whether
monthly dosing will indeed yield enhanced
compliance or improved health outcomes in
the prevention or treatment of post-menopau-
sal osteoporosis.
It is clear that the personal and economic
burden of osteoporosis is substantial, if not
staggering, to patients, their families and society
at large.
76 In the US, doctors and patients are
not at a loss for diﬀerent choices of osteoporosis
medications. Today’s challenge is to achieve
reasonable persistence to a long-term medication
regimen for a largely silent disease. Unfortu-
nately, to date, we have been losing the persist-
ency battle in osteoporosis. Payers, doctors and
patients should openly welcome new advances in
pharmaceutical therapy for osteoporosis
because what may work for one patient may not
work for another. At the same time, payers,
doctors and patients may realize more gains
from their investments in prescription osteo-
porosis therapy if a patient-centred and
preference-sensitive approach to medication
decision-making is embraced and compliance is
ultimately enhanced.
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